McKay Caroline, Bolzani Anna, Kienzle Scarlette, Geransar Parnia, Panés Julian
Global Evidence & Outcomes, Takeda Pharmaceuticals USA, Inc., Cambridge, MA 02139, United States.
Real World Evidence, Cytel Inc., Berlin 10785, Germany.
World J Gastrointest Surg. 2025 Jul 27;17(7):101767. doi: 10.4240/wjgs.v17.i7.101767.
Data regarding complex Crohn's perianal fistulas (CPF) epidemiology are limited, and optimal treatment strategies are elusive. An improved understanding of how CPF treatment options are used in the real-world setting and factors associated with CPF development, treatment failure, and reasons for undergoing multiple surgeries may help to inform optimal patient management strategies, reduce treatment burden, and improve outcomes in patients with CPF.
To describe the epidemiology, treatments, outcomes, and associated risk/protective factors for complex CPF.
Electronic databases (MEDLINE, EMBASE, EBM Reviews, EconLit) were searched. Two reviewers independently used populations, interventions, comparators, outcomes, study designs, and time criteria to identify relevant studies. Observational studies published in English from January 1, 2015 to February 17, 2022 with > 50 patients were included, even if complex CPF was not defined. Items of interest included complex CPF definitions, epidemiology, treatment patterns, morbidity, mortality, and risk factors associated with complex CPF development, treatment failure, and undergoing multiple surgeries. Data were reported using descriptive statistics.
Overall, 140 studies were included. Complex CPF definitions were heterogeneous and rarely reported (24 studies). Hence, data mostly related to CPF in general. CPF prevalence was variable (range: 1.5%-81.0%). Incidence was wide-ranging and mostly reported cumulatively at 1-year post-Crohn's disease diagnosis (range: 3.5%-50.1%). Overall healing and failure rates after treatment were in the range of 10.5%-80.2% and 3.6%-83.0%, respectively. Abscesses were the most frequently reported morbidity ( 18). No CPF-related deaths were reported. No consistent risk or protective factors were identified.
Epidemiology, treatment patterns, and risk factors for CPF vary, likely due to inconsistent CPF and clinical outcome definitions. Standardization would facilitate comparability, which may inform optimal complex CPF treatment strategies.
关于复杂性克罗恩肛周瘘管(CPF)流行病学的数据有限,最佳治疗策略难以确定。更好地了解CPF治疗方案在现实环境中的使用情况以及与CPF发生、治疗失败和接受多次手术的原因相关的因素,可能有助于为最佳患者管理策略提供信息,减轻治疗负担,并改善CPF患者的治疗结果。
描述复杂性CPF的流行病学、治疗方法、治疗结果以及相关风险/保护因素。
检索电子数据库(MEDLINE、EMBASE、循证医学评论、经济文献数据库)。两名评审员独立使用人群、干预措施、对照、结果、研究设计和时间标准来识别相关研究。纳入2015年1月1日至2022年2月17日发表的英文观察性研究,研究对象超过50例,即使未定义复杂性CPF。感兴趣的项目包括复杂性CPF的定义、流行病学、治疗模式、发病率、死亡率以及与复杂性CPF发生、治疗失败和接受多次手术相关的风险因素。数据采用描述性统计报告。
总共纳入140项研究。复杂性CPF的定义各不相同,且很少有研究报告(24项研究)。因此,数据大多与一般CPF相关。CPF患病率各不相同(范围:1.5%-81.0%)。发病率范围广泛,大多在克罗恩病诊断后1年累计报告(范围:3.5%-50.1%)。治疗后的总体愈合率和失败率分别在10.5%-80.2%和3.6%-83.0%范围内。脓肿是最常报告的并发症(18)。未报告与CPF相关的死亡病例。未确定一致的风险或保护因素。
CPF的流行病学、治疗模式和风险因素各不相同,可能是由于CPF和临床结局定义不一致。标准化将有助于可比性,这可能为最佳复杂性CPF治疗策略提供信息。